Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373533 | 0.89 | GRM3 (0.55) | GRM3FOLH1 | |
| SCHEMBL7607528 | 0.86 | GRM3 (0.52) | GRM3FOLH1 | |
| SCHEMBL5053383 | 0.82 | FDPS (0.51) | FOLH1FDPSPTPRA | |
| SCHEMBL5052894 | 0.81 | CPA3 (0.71) | GRM3FOLH1CPA3 | |
| SCHEMBL2368046 | 0.80 | FOLH1 (0.46) | GRM3FOLH1PTPRACPA3 | |
| SCHEMBL2368044 | 0.78 | FOLH1 (0.44) | GRM3FOLH1PTPRACPA3 | |
| SCHEMBL5059809 | 0.78 | FOLH1 (0.52) | GRM3FOLH1CPA3 | |
| SCHEMBL6422716 | 0.77 | ANPEP (0.57) | GRM3FOLH1FDPSCPA3 | |
| SCHEMBL2368049 | 0.76 | FOLH1 (0.46) | GRM3FOLH1PTPRACPA3 | |
| SCHEMBL12145183 | 0.76 | GRM3 (0.68) | GRM3FOLH1CPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-6071965-A | TO INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY AND TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-06 | — | — | US | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1093453-B1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARM INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1571141-A2 | Naaladase inhibitors useful as pharmaceutical compounds and compositions | GUILFORD PHARMACEUTICALS INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6806261-B2 | CONTROL RELEASE TRANSFORMING GROWTH FACTOR; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIPROLIFERATIVE AGENT | GUILFORD PHARMACEUTICALS INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1371367-A1 | Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases | GUILFORD PHARMACEUTICALS INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1140048-B1 | USE OF NAALADASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN DISEASES | GUILFORD PHARM INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | JACKSON PAUL F (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| EP-1202717-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6376478-B1 | N-ACETYLATED (ALPHA)-LINKED ACIDIC DIPEPTIDASE INHIBITOR; BLOCKS RELEASE OF GLUTAMTE PRE-SYNAPTICALLY FOR REDUCED TOXICITY | GUILFORD PHARMACEUTICALS INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1140048-A2 | METHODS FOR TREATING CERTAIN DISEASES USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6228888-B1 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1093453-A1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2001001974-A2 | NAALADASE INHIBITORS IN ANXIETY AND MEMORY DISORDERS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000038785-A2 | METHODS FOR TREATING CERTAIN DISEASES USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6071965-A | TO INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY AND TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-06 | — | — | US | disclosed |
| WO-2000001668-A2 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | GRM3 3659/4885FOLH1 56/4885FDPS 630/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | GRM3 2045/4885FOLH1 1/4885FDPS 3410/4885 |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | NAALAD2, DNPEP, NAAA | GRM3 305/4885FOLH1 22/4885FDPS 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.